Equities

Medinet Co Ltd

2370:TYO

Medinet Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)42.00
  • Today's Change1.00 / 2.44%
  • Shares traded1.32m
  • 1 Year change-14.29%
  • Beta2.2398
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MEDINET Co., Ltd. is a Japan-based company mainly engaged in cell processing industry and cellular medical products business. It operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. It also provides comprehensive support services for immune cell therapy.

  • Revenue in JPY (TTM)759.11m
  • Net income in JPY-1.34bn
  • Incorporated1995
  • Employees98.00
  • Location
    Medinet Co Ltd9F, TRC Center Bldg., 6-1-1, HeiwajimaOTA-KU 143-0006JapanJPN
  • Phone+81 366311201
  • Fax+81 366311202
  • Websitehttps://www.medinet-inc.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Carna Biosciences, Inc.1.40bn-1.51bn5.73bn67.00--2.04--4.09-85.98-85.9880.34147.090.3911.1913.5920,922,580.00-42.15-14.45-45.45-16.9587.5390.59-107.80-35.4211.11--0.0215--17.2416.5914.57---27.69--
Veritas In Silico Inc-100.00bn-100.00bn5.93bn15.00--2.52----------363.16------------------------63.22--0.00--101.54--123.38------
Chiome Bioscience Inc587.30m-1.12bn6.49bn51.00--5.48--11.06-21.19-21.1911.0918.990.36224.687.9611,515,750.00-69.09-50.50-96.39-57.3855.2857.53-190.76-224.743.17-816.710.2144--8.1926.241.84------
Noile-Immune Biotech Inc308.06m-979.88m7.10bn28.00--1.42--23.05-22.63-22.637.11115.620.05490.06256.3511,002,180.00-17.47---17.90--99.80---318.08--66.40--0.00---49.37---192.28------
TMS Co Ltd0.00-1.10bn7.86bn14.00--2.63-----28.37-28.370.0074.100.00----0.00-33.57---34.42----------31.13--0.00-------11.51------
Modalis Therapeutics Corp0.00-1.87bn7.91bn37.00--2.57-----52.79-52.790.0044.350.00----0.00-74.95-29.19-78.46-30.02-------597.3543.87-87.460.0771---100.00--11.50--135.50--
OncoTherapy Science, Inc.478.75m-1.12bn8.69bn54.00--8.69--18.16-4.83-4.832.083.680.35264.349.778,865,722.00-82.71-55.67-106.53-63.82-32.12-1.49-234.61-247.473.11--0.0731---46.2416.81-15.15---48.33--
Linical Co Ltd12.15bn252.44m9.05bn662.0032.751.0111.500.745111.1811.18538.03362.320.6633--3.4518,356,870.001.384.012.376.3329.2630.992.085.48----0.251850.81-1.671.70-66.32-9.86-10.184.56
3-D Matrix Ltd5.25bn-1.05bn10.95bn106.00--9.52--2.09-12.89-12.8966.8811.660.85590.5515.4049,502,420.00-17.15-42.10-21.31-55.6068.3853.95-20.04-96.032.51--0.7979--98.3069.4189.55---30.34--
Tsubota Laboratory Inc674.29m-691.35m11.00bn7.00--9.22--16.31-27.06-27.0626.3846.620.29741.83465.3596,327,430.00-30.50---42.97--7.89---102.53--2.20-434.240.085---29.45---811.14------
Medinet Co Ltd759.11m-1.34bn11.11bn98.00--2.07--14.64-5.53-5.533.1020.310.134711.643.737,745,980.00-23.85-21.05-24.99-22.4717.7828.75-177.09-135.4018.90--0.00--4.40-7.90-14.66---17.67--
Nano Mrna Co Ltd76.60m-650.31m11.58bn18.00--3.54--151.21-9.24-9.241.0946.270.014524.081.454,255,556.00-12.33-24.16-13.57-25.1778.3084.69-848.97-600.709.24--0.2540---32.98-22.8840.50------
PRISM BioLab Co Ltd-100.00bn-100.00bn11.69bn22.00--5.53----------58.79----------------------------0.00---79.63---822.18------
AnGes Inc521.96m-9.80bn13.10bn145.00--0.555--25.09-45.15-45.152.4286.480.01740.232411.183,599,697.00-32.66-28.50-36.48-33.1437.0839.42-1,876.83-6,726.822.36-12.150.0672--128.13-24.1749.45--12.11--
Chordia Therapeutics Inc0.00-1.83bn13.99bn21.00--3.35-----31.95-31.950.0061.49---------------------------500.25---------918.09------
Data as of Nov 08 2024. Currency figures normalised to Medinet Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.71%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 03 Oct 20241.31m0.50%
SSgA Funds Management, Inc.as of 03 Oct 2024558.70k0.21%
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.